Gene info: ID 54413

Gene: NLGN3

GENE ID: 54413

Synonyms: HNL3

Description: neuroligin 3

Gene type: protein-coding

Location: Xq13.1

dbXrefs: Ensembl:ENSG00000196338 MIM:300336 Vega:OTTHUMG00000021790 UniprotKB:Q9NZ94

RefSeq: NG_015874.1

Retrived from: PubMed

SNPs: 0 ANCO-SNPs

Phenotype: CD

# Publications: 1

Sherlock p-value : NA (AD) NA (ND) (Frontal_Cortex)

Pascal p-value : NA (AD) NA (ND)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol	Pearson Correlation Coefficient
GRM3	0.835
CSPG5	0.832
ASIC1	0.828
NCAN	0.825
SLC6A1	0.813
SALL2	0.807
GABBR1	0.806
LRP1	0.794
SUOX	0.79
OGDH	0.789

Top 10 negatively co-expressed genes

Gene Symbol	Pearson Correlation Coefficient
OR4F5	-0.676
OR4F29	-0.624
GBP2	-0.365
SFN	-0.357
BCL2A1	-0.348
CXCL3	-0.341
KYNU	-0.336
CHI3L2	-0.335
CLEC6A	-0.334
TNFAIP8	-0.334

There is no DrugBank record for this gene !

ID	Drug Name	Action	PubMed
C511295	2,2',4,4'-tetrabromodiphenyl ether	"2,2',4,4'-tetrabromodiphenyl ether results in decreased expression of NLGN3 mRNA"	27291303
C459179	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	"[NOG protein co-treated with belinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NLGN3 mRNA"	27188386
C459179	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NLGN3 mRNA"	27188386
C459179	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NLGN3 mRNA"	27188386
C516138	(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine	"[NOG protein co-treated with belinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NLGN3 mRNA"	27188386
C516138	(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine	"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NLGN3 mRNA"	27188386
C516138	(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine	"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NLGN3 mRNA"	27188386
D020106	Acrylamide	Acrylamide results in decreased expression of NLGN3 mRNA	28959563
D000643	Ammonium Chloride	Ammonium Chloride affects the expression of NLGN3 mRNA	16483693
D001280	Atrazine	Atrazine results in decreased expression of NLGN3 mRNA	25929836
D001374	Azacitidine	Azacitidine results in increased expression of NLGN3 mRNA	20823114
C487081	belinostat	belinostat results in decreased expression of NLGN3 mRNA	26272509
C487081	belinostat	"[NOG protein co-treated with belinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NLGN3 mRNA"	27188386
D001564	Benzo(a)pyrene	Benzo(a)pyrene results in increased expression of NLGN3 mRNA	22316170
D004958	Estradiol	Estradiol results in increased expression of NLGN3 mRNA	22411564
D004958	Estradiol	Progesterone inhibits the reaction [Estradiol results in increased expression of NLGN3 mRNA]	22411564
C006780	bisphenol A	bisphenol A results in decreased expression of NLGN3 mRNA	23719926
C006780	bisphenol A	bisphenol A results in decreased expression of NLGN3 mRNA	25181051
C006780	bisphenol A	bisphenol A results in increased expression of NLGN3 mRNA	29097150
C018475	butyraldehyde	butyraldehyde results in decreased expression of NLGN3 mRNA	26079696
C010902	decabromobiphenyl ether	decabromobiphenyl ether results in increased expression of NLGN3 mRNA	23914054
D003993	Dibutyl Phthalate	Dibutyl Phthalate results in increased expression of NLGN3 mRNA	21266533
D002945	Cisplatin	[Cisplatin co-treated with jinfukang] results in decreased expression of NLGN3 mRNA	27392435
D004041	Dietary Fats	Dietary Fats results in decreased expression of NLGN3 mRNA	25016146
D004997	Ethinyl Estradiol	Ethinyl Estradiol results in increased expression of NLGN3 mRNA	29097150
D005038	Ethylnitrosourea	Ethylnitrosourea results in increased mutagenesis of NLGN3 gene	16495775
D005419	Flavonoids	Flavonoids results in decreased expression of NLGN3 mRNA	18035473
C069837	fullerene C60	fullerene C60 results in decreased expression of NLGN3 mRNA	19167457
C544151	jinfukang	[Cisplatin co-treated with jinfukang] results in decreased expression of NLGN3 mRNA	27392435
C544151	jinfukang	jinfukang results in decreased expression of NLGN3 mRNA	27392435
D007854	Lead	Lead affects the expression of NLGN3 mRNA	28903495
D007854	Lead	Lead affects the splicing of NLGN3 mRNA	28903495
C028007	nickel monoxide	nickel monoxide results in decreased expression of NLGN3 mRNA	19167457
C009618	O,O-diethyl O-3,5,6-trichloro-2-pyridyl phosphate	"PON1 gene polymorphism affects the susceptibility to [O,O-diethyl O-3,5,6-trichloro-2-pyridyl phosphate affects the expression of NLGN3 mRNA]"	21673326
C009618	O,O-diethyl O-3,5,6-trichloro-2-pyridyl phosphate	"O,O-diethyl O-3,5,6-trichloro-2-pyridyl phosphate results in decreased expression of NLGN3 mRNA"	21673326
C009618	O,O-diethyl O-3,5,6-trichloro-2-pyridyl phosphate	"PON1 protein affects the reaction [O,O-diethyl O-3,5,6-trichloro-2-pyridyl phosphate results in decreased expression of NLGN3 mRNA]"	21673326
D010100	Oxygen	Oxygen deficiency results in increased expression of NLGN3 mRNA	16373842
D010100	Oxygen	Simvastatin inhibits the reaction [Oxygen deficiency results in increased expression of NLGN3 mRNA]	16373842
D052638	Particulate Matter	Particulate Matter affects the methylation of NLGN3 promoter	28153600
D052638	Particulate Matter	Particulate Matter results in decreased expression of NLGN3 mRNA	28153600
D010662	Phenylmercuric Acetate	"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NLGN3 mRNA"	27188386
D010662	Phenylmercuric Acetate	Phenylmercuric Acetate results in decreased expression of NLGN3 mRNA	26272509
D011374	Progesterone	Progesterone inhibits the reaction [Estradiol results in increased expression of NLGN3 mRNA]	22411564
D019821	Simvastatin	Simvastatin inhibits the reaction [Oxygen deficiency results in increased expression of NLGN3 mRNA]	16373842
D014212	Tretinoin	Tretinoin results in decreased expression of NLGN3 mRNA	21934132
C012589	trichostatin A	"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NLGN3 mRNA"	27188386
C012589	trichostatin A	trichostatin A results in decreased expression of NLGN3 mRNA	26272509
D014635	Valproic Acid	Valproic Acid results in decreased expression of NLGN3 mRNA	23179753\|2800136
C111237	vorinostat	vorinostat results in decreased expression of NLGN3 mRNA	27188386

GO/Pathway

GO ID	GO Term	Qualifier	Evidence	PubMed
GO:0005515	protein binding	-	IPI	17292328
GO:0038023	signaling receptor activity	-	ISS	-
GO:0042043	neurexin family protein binding	-	IBA	21873635
GO:0042043	neurexin family protein binding	-	ISS	15152050
GO:0050839	cell adhesion molecule binding	-	ISS	15152050
GO:0097110	scaffold protein binding	-	IPI	17292328

GO ID	GO Term	Qualifier	Evidence	PubMed
GO:0002087	regulation of respiratory gaseous exchange by neurological system process	-	ISS	-
GO:0006898	receptor-mediated endocytosis	-	ISS	-
GO:0007158	neuron cell-cell adhesion	-	IBA	21873635
GO:0007158	neuron cell-cell adhesion	-	ISS	-
GO:0007416	synapse assembly	-	ISS	-
GO:0007612	learning	-	IMP	12669065
GO:0008542	visual learning	-	IEA	-
GO:0030534	adult behavior	-	IMP	12669065
GO:0035176	social behavior	-	IMP	12669065
GO:0048675	axon extension	-	ISS	-
GO:0048709	oligodendrocyte differentiation	-	IEA	-
GO:0050804	modulation of chemical synaptic transmission	-	IBA	21873635
GO:0050804	modulation of chemical synaptic transmission	-	ISS	-
GO:0050808	synapse organization	-	IMP	15150161
GO:0051965	positive regulation of synapse assembly	-	ISS	-
GO:0051968	positive regulation of synaptic transmission, glutamatergic	-	ISS	-
GO:0060024	rhythmic synaptic transmission	-	ISS	-
GO:0060079	excitatory postsynaptic potential	-	IEA	-
GO:0060080	inhibitory postsynaptic potential	-	ISS	-
GO:0060291	long-term synaptic potentiation	-	IEA	-
GO:0061002	negative regulation of dendritic spine morphogenesis	-	IEA	-
GO:0071625	vocalization behavior	-	IMP	12669065
GO:0090394	negative regulation of excitatory postsynaptic potential	-	IEA	-
GO:0097104	postsynaptic membrane assembly	-	IBA	21873635
GO:0097104	postsynaptic membrane assembly	-	ISS	-
GO:0097105	presynaptic membrane assembly	-	IBA	21873635
GO:0097105	presynaptic membrane assembly	-	ISS	-
GO:0099054	presynapse assembly	-	TAS	21838267
GO:1900271	regulation of long-term synaptic potentiation	-	IEA	-
GO:2000310	regulation of NMDA receptor activity	-	IEA	-
GO:2000331	regulation of terminal button organization	-	IEA	-
GO:2000463	positive regulation of excitatory postsynaptic potential	-	ISS	-
GO:2000809	positive regulation of synaptic vesicle clustering	-	IEA	-
GO:2000969	positive regulation of AMPA receptor activity	-	ISS	-

GO ID	GO Term	Qualifier	Evidence	PubMed
GO:0005886	plasma membrane	-	TAS	-
GO:0005887	integral component of plasma membrane	-	IBA	21873635
GO:0009986	cell surface	-	IBA	21873635
GO:0009986	cell surface	-	IDA	15150161 17292328
GO:0030054	cell junction	-	IEA	-
GO:0030139	endocytic vesicle	-	ISS	-
GO:0045202	synapse	-	IBA	21873635
GO:0045202	synapse	-	ISS	-
GO:0060076	excitatory synapse	-	IDA	15620359
GO:0089717	spanning component of membrane	-	TAS	21838267
GO:0098983	symmetric, GABA-ergic, inhibitory synapse	-	TAS	21838267
GO:0098985	asymmetric, glutamatergic, excitatory synapse	-	TAS	21838267
GO:0099055	integral component of postsynaptic membrane	-	ISS	-

KEGG ID	KEGG Term
hsa04514	Cell adhesion molecules (CAMs)

Reactome ID	Reactome Term	Evidence
R-HSA-112316	Neuronal System	IEA
R-HSA-112316	Neuronal System	TAS
R-HSA-6794361	Neurexins and neuroligins	IEA
R-HSA-6794361	Neurexins and neuroligins	TAS
R-HSA-6794362	Protein-protein interactions at synapses	IEA
R-HSA-6794362	Protein-protein interactions at synapses	TAS

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID	Title (Year)	Author	Journal
18418251	Nrxn3 upregulation in the globus pallidus of mice developing cocaine addiction. (2008 May 7)	Kelai S	Neuroreport